Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-15 |
2024-03 |
-0.41 |
-0.23 |
0.18 |
43.90% |
2024-03-25 |
2023-12 |
-0.57 |
N/A |
N/A |
N/A |
2023-11-13 |
2023-09 |
-1.02 |
N/A |
N/A |
N/A |
2023-11-13 |
2023-09 |
-1.02 |
-0.35 |
0.67 |
65.69% |
Date |
Firm |
Action |
From |
To |
2023-08-07 |
Goldman Sachs |
Upgrade |
|
Buy |
2023-08-07 |
JMP Securities |
Upgrade |
|
Market Outperform |
2023-08-07 |
Piper Sandler |
Upgrade |
|
Overweight |
2023-08-07 |
TD Cowen |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-03-25 |
HAPPEL DAVID |
Chief Executive Officer |
639.20K |
Purchase |
2023-11-16 |
KEMBLE GEORGE |
Officer and Director |
156.38K |
Stock Award(Grant) |
2023-07-17 |
KPCB PBD ASSOCIATES L L C |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2023-11-16 |
MARTINS EDUARDO BRUNO |
Officer |
89.57K |
Stock Award(Grant) |
2023-07-17 |
NEW ENTERPRISE ASSOCIATES 13, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2023-07-17 |
PARSEY MERDAD |
Director |
12.79K |
Stock Award(Grant) |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
Fidelity Growth Company Fund |
635.04K |
7.67M |
2.97% |
2023-07-30 |
Fidelity Blue Chip Growth Fund |
278.50K |
4.44M |
1.30% |
2023-07-30 |
Fidelity Advisor Biotechnology Fund |
179.77K |
2.87M |
0.84% |
2023-08-30 |
Fidelity Series Growth Company Fund |
175.10K |
2.12M |
0.82% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
145.86K |
1.76M |
0.68% |
2023-07-30 |
USAA Mutual Fund Tr-Science & Technology Fund |
57.04K |
909.79K |
0.27% |